This piece explores the medtech sector’s response to impending tariffs under the Trump administration. Streamliners’ CEO, Andreas Haag, shares insights on how these tariffs could disrupt global supply chains, particularly for companies reliant on imported components. He emphasizes the need for medtech firms to reassess their sourcing strategies and consider domestic manufacturing options, despite higher costs. Haag also highlights the importance of operational excellence and supply chain optimization to navigate these challenges effectively.
Read on
